Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Spectrum to Acquire Allos in Deal Valued at $206M(2)

By Pharmaceutical Processing | April 5, 2012

HENDERSON, Nev. (AP) — Spectrum Pharmaceuticals said today it signed an agreement to acquire Allos Therapeutics Inc. in a deal valued at up to $206 million.

Spectrum, based in Henderson, Nev., will pay $1.82 per share for each outstanding share of Allos, a 28 percent premium over its closing price in Wednesday.

Allos shareholders will also a contingent value right to an additional payment of 11 cents per share if it achieves some European regulatory and commercialization milestones for the cancer drug Folotyn.

Shares of Allos, which is based in Westminster, Colo. closed at $1.43 Wednesday and have fallen steadily since closing above $3 about a year ago.

The boards of directors for both companies have unanimously approved the deal.

Folotyn is approved in the U.S. as a treatment for peripheral T-cell lymphoma in patients who have suffered a relapse or who have not responded to previous treatment.

Spectrum sells two oncology drugs, Zevalin, which is approved to treat a form of non-Hodgkin’s lymphoma, and Fusilev, which treats the side effects of methotrexate, a drug used in chemotherapy.

Spectrum Chairman and CEO Dr. Rajesh C. Shrotriya said in a statement the deal accelerates its hematology franchise development and “affirms our commitment to becoming a leader in the treatment of lymphoma.”

 

 

Related Articles Read More >

This is the logo of Hikma.
Hikma to spend another $1B on US manufacturing, R&D
Sandoz Logo 2025
Sandoz breaks ground on biosimilar plant in Slovenia
Nymi Logo_2022 (1)
Nymi, Caliber partner on passwordless authentication for pharma manufacturing
Building a resilient pharma supply chain
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE